Evidence map›Paper›PMID 26622501›Full record

ArticleExperimental and therapeutic medicine2015

Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer.

Liying Guo, Dilimina Yilamu, Liting Sun, Sha Liu, Fangjing Ma

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Liying GuoDepartment of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China.
Dilimina YilamuDepartment of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China.
Liting SunDepartment of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China.
Sha LiuDepartment of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China.
Fangjing MaDepartment of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China.
First Affiliated Hospital of Xinjiang Medical University · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-catenin, cyclin D1 and estrogen receptor (ER)-β are closely associated with the pathogenesis of breast cancer. In the present study, tissue samples were collected from 226 patients with breast cancer. Subsequently, immunohistochemical analysis was performed to detect the expression of β-catenin, cyclin D1 and ER-β, and the Kaplan-Meier method was used for survival analysis. The abnormal expression rate of β-catenin was 75.2%, while the cyclin D1 positive expression rate was 77.0% and the ER-β positive expression rate was 43.4%. In the tissue samples exhibiting abnormal expression of β-catenin, the positive expression rate of cyclin D1 (85.9%) was significantly higher compared with the samples that expressed β-catenin normally (50.0%). Furthermore, the positive expression rate of ER-β (35.7%) in the β-catenin normal expression tissues was significantly lower compared with that in the β-catenin abnormal expression tissues (45.9%). In the tissues with positive cyclin D1 expression, the positive expression rate of ER-β (48.4%) was significantly higher compared with the cyclin D1 negative expression samples (26.9%). In addition, patients with normal expression of β-catenin and positive expression of cyclin D1 exhibited longer tumor-free survival times. Therefore, an association exists among the abnormal expression of β-catenin and the positive expression of cyclin D1 and ER-β, which may contribute to the development of breast cancer.

Indexed as

cyclin D1estrogen receptor-βhuman breast cancerWnt signaling pathwayβ-catenin

Identifiers

PMID26622501
PMCPMC4578070
OpenAlexW2106517313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.